Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

KNOXVILLE, Tenn. – Kalen DeBoer's message to Alabama football Saturday night after the Crimson Tide's 24-17 loss to Tennessee was simple. Look inward. Do some soul-searching. Get back to work.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

But between shortages, high out of pocket costs and the need for weekly injections, the medication is not suited for everyone ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

With the hope of enhancing wellness in North Platte, cousins and co-owners Jacque Stittle and Natasha Jarvis-Burch opened Elevate IVy.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Altimmune’s lead drug Pemvidutide demonstrates significant progress in obesity and liver health. See why ALT stock is a ...